Teleflex Incorporated (NYSE:TFX) Given Consensus Rating of "Hold" by Analysts

Key Points

• Analysts give Teleflex a consensus rating of Hold from 10 firms (2 sell, 5 hold, 3 buy) with an average 12‑month price target of $138.50.
• Teleflex's latest quarter significantly missed expectations—EPS $1.93 vs. $3.73 expected and revenue $569M vs. $912.57M—revenue fell 28.5% year‑over‑year and net margin was -30.56%; the company set FY2026 guidance of $6.25–$6.55 EPS.
• Institutional investors own 95.62% of the stock; Teleflex pays a $0.34 quarterly dividend (1.1% yield) but has a negative payout ratio and negative P/E, reflecting recent earnings weakness.

Teleflex Incorporated (NYSE:TFX - Get Free Report) has been assigned an average recommendation of "Hold" from the ten research firms that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $138.50.

A number of research firms have recently issued reports on TFX. Raymond James Financial raised Teleflex from a "market perform" rating to an "outperform" rating and set a $128.00 price target on the stock in a research report on Friday, March 27th. Needham & Company LLC increased their price target on Teleflex from $138.00 to $147.00 and gave the stock a "buy" rating in a research report on Thursday, February 26th. Zacks Research downgraded Teleflex from a "hold" rating to a "strong sell" rating in a research report on Monday, March 2nd. Royal Bank Of Canada increased their price target on Teleflex from $115.00 to $125.00 and gave the stock a "sector perform" rating in a research report on Friday, February 27th. Finally, Wells Fargo & Company increased their price target on Teleflex from $116.00 to $130.00 and gave the stock an "equal weight" rating in a research report on Friday, February 27th.

Institutional Investors Weigh In On Teleflex

A number of institutional investors have recently added to or reduced their stakes in the stock. MassMutual Private Wealth & Trust FSB boosted its position in Teleflex by 57.9% during the third quarter. MassMutual Private Wealth & Trust FSB now owns 210 shares of the medical technology company's stock valued at $26,000 after purchasing an additional 77 shares in the last quarter. Banque Cantonale Vaudoise boosted its position in Teleflex by 82.5% during the fourth quarter. Banque Cantonale Vaudoise now owns 250 shares of the medical technology company's stock valued at $31,000 after purchasing an additional 113 shares in the last quarter. Hantz Financial Services Inc. boosted its position in Teleflex by 40.5% during the fourth quarter. Hantz Financial Services Inc. now owns 392 shares of the medical technology company's stock valued at $48,000 after purchasing an additional 113 shares in the last quarter. UMB Bank n.a. boosted its position in Teleflex by 57.1% during the fourth quarter. UMB Bank n.a. now owns 311 shares of the medical technology company's stock valued at $38,000 after purchasing an additional 113 shares in the last quarter. Finally, Maryland State Retirement & Pension System boosted its position in Teleflex by 1.5% during the fourth quarter. Maryland State Retirement & Pension System now owns 8,652 shares of the medical technology company's stock valued at $1,056,000 after purchasing an additional 129 shares in the last quarter. Institutional investors own 95.62% of the company's stock.

Teleflex Price Performance

TFX opened at $123.22 on Tuesday. Teleflex has a 12-month low of $100.18 and a 12-month high of $138.93. The company has a current ratio of 2.54, a quick ratio of 2.01 and a debt-to-equity ratio of 0.81. The business's fifty day simple moving average is $112.24 and its 200-day simple moving average is $116.05. The company has a market capitalization of $5.45 billion, a price-to-earnings ratio of -6.00, a PEG ratio of 0.74 and a beta of 0.84.

Teleflex (NYSE:TFX - Get Free Report) last posted its quarterly earnings results on Thursday, February 26th. The medical technology company reported $1.93 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.73 by ($1.80). Teleflex had a positive return on equity of 14.30% and a negative net margin of 30.56%.The firm had revenue of $569.00 million for the quarter, compared to the consensus estimate of $912.57 million. During the same period in the previous year, the company posted $3.89 EPS. Teleflex's quarterly revenue was down 28.5% compared to the same quarter last year. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. On average, equities research analysts anticipate that Teleflex will post 13.98 earnings per share for the current fiscal year.

Teleflex Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 31st. Investors of record on Friday, March 6th were given a dividend of $0.34 per share. The ex-dividend date of this dividend was Friday, March 6th. This represents a $1.36 dividend on an annualized basis and a yield of 1.1%. Teleflex's dividend payout ratio (DPR) is presently -6.62%.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company's offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.